|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 The Scripps Research Institute – Florida, Department of Infectology, 130 Scripps Way, #3C1 Jupiter, FL 33458, USA
2 Institut de Biologie et Chimie des Protéines, UMR5086, CNRS-Université Lyon I, IFR128, 7 Passage du Vercors, 69367 Lyon Cedex 07, France
Correspondence
A. D. Strosberg
strosber{at}scripps.edu
Hepatitis C virus (HCV) nucleocapsid assembly requires dimerization of the core protein, an essential step in the formation of the virus particle. We developed a novel quantitative assay for monitoring this protein–protein interaction, with the goal of identifying inhibitors of core dimerization that might block HCV production in infected Huh-7.5 hepatoma cells. Two core-derived, 18-residue peptides were found that inhibited the dimerization of a fragment of core comprising residues 1–106 (core106) by 68 and 63 %, respectively. A third, related 15-residue peptide displayed 50 % inhibition, with an IC50 of 21.9 µM. This peptide was shown, by fluorescence polarization, to bind directly to core106 with a Kd of 1.9 µM and was displaced by the unlabelled peptide with an IC50 of 18.7 µM. When measured by surface plasmon resonance, the same peptide bound core169 with a Kd of 7.2 µM. When added to HCV-infected cells, each of the three peptides blocked release, but not replication, of infectious virus. When measured by real-time RT-PCR, the RNA levels were reduced by 7-fold. The 15-residue peptide had no effect on HIV propagation. Such inhibitors may constitute useful tools to investigate the role of core dimerization in the virus cycle.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |